ストックスクリーナーアプリを入手
3.02
5.92%
-0.19
前日終値:
$3.21
開ける：
$3.19
24時間の取引高:
1.13M
Relative Volume:
0.73
時価総額：
$298.59M
収益：
$58.36M
当期純損益:
$-25.72M
株価収益率:
-8.2944
EPS:
-0.3641
ネットキャッシュフロー:
$-24.91M
1週間 パフォーマンス:
-5.92%
1か月 パフォーマンス:
+11.03%
6か月 パフォーマンス:
-36.02%
1年 パフォーマンス:
-29.11%
1日の値動き範囲:
$2.975
$3.20
1週間の範囲:
$2.975
$3.39
52週間の値動き範囲:
$2.24
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
名前
Aquestive Therapeutics Inc
セクター
電話
908-941-1900
住所
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.02 | 298.59M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2019-04-22 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-03 | 開始されました | Lake Street | Buy |
| 2018-08-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-08-20 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aquestive Therapeutics Inc (AQST) 最新ニュース
Bank of New York Mellon Corp Reduces Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy - Seeking Alpha
Aquestive Therapeutics: Not For Me, But Attractive (NASDAQ:AQST) - Seeking Alpha
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark - Simply Wall St
What is HC Wainwright’s Estimate for AQST Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for AQST FY2026 Earnings? - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright - Defense World
Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Aquestive Therapeutics Advances Product Pipeline and Market Access - TipRanks
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call Transcript - Insider Monkey
Buy Rating on Aquestive Therapeutics Driven by Anaphylm’s Regulatory Progress and Strategic Launch Preparations - TipRanks
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings - MSN
Lake Street Capital Lowers Aquestive Therapeutics (NASDAQ:AQST) Price Target to $8.00 - Defense World
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts - Yahoo Finance
Aquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global Partners - TipRanks
New York State Common Retirement Fund Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Aquestive Therapeutics: Strategic Advancements and Financial Strength Underpin Buy Rating - TipRanks
Earnings call transcript: Aquestive Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com UK
Earnings call transcript: Aquestive Therapeutics Q4 2024 misses estimates - Investing.com
Aquestive Therapeutics: Q4 Earnings Snapshot - Midland Daily News
Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates - MSN
Aquestive Therapeutics Q4 Net Loss Widens, Revenue Falls; 2025 Revenue Outlook Issued - Marketscreener.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Aquestive Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics - Nasdaq
Aquestive Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aquestive Therapeutics reports Q4 EPS (19c), consensus (13c) - TipRanks
Aquestive Therapeutics misses Q4 estimates, shares fall By Investing.com - Investing.com South Africa
Aquestive Therapeutics misses Q4 estimates, shares fall - Investing.com India
Aquestive Therapeutics Initiates Anaphylm NDA Filing Process - TipRanks
Aquestive Therapeutics sees FY25 revenue $47M-$56M , consensus $52.97M - TipRanks
Aquestive Therapeutics: Q4 Earnings Snapshot -March 05, 2025 at 04:19 pm EST - Marketscreener.com
Aquestive Therapeutics Q4 Earnings: Anaphylm NDA Filing Process Begins as Annual Revenue Grows 14% - StockTitan
Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Wednesday - Defense World
Aquestive Therapeutics (AQST) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March - The Manila Times
Aquestive Therapeutics Sets March Conference Schedule: Key Dates for Investor Access - StockTitan
Aquestive Therapeutics' SWOT analysis: PharmFilm tech could disrupt epinephrine stock By Investing.com - Investing.com South Africa
Aquestive Therapeutics' SWOT analysis: PharmFilm tech could disrupt epinephrine stock - Investing.com India
Aquestive Therapeutics’ SWOT analysis: PharmFilm tech could disrupt epinephrine stock - Investing.com
Aquestive Therapeutics Inc (AQST) 財務データ
収益
当期純利益
現金流量
EPS
3.70%
0.05%
大文字化:
|
ボリューム (24 時間):